Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo tackles lung cancer brain spread after standard drug fails

NCT ID NCT07361705

Not yet recruiting Disease control Sponsor: Alpha Biopharma (Jiangsu) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jan 31, 2026 · Last updated May 22, 2026 · Updated 17 times

Summary

This early-stage trial tests whether adding a new drug, zorifertinib, to the existing drug osimertinib is safe and helpful for people with advanced lung cancer that has spread to the brain and spinal cord lining after osimertinib stopped working. About 42 participants will receive the combination to find the best dose and check for side effects. The goal is to control the disease, not cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH MENINGEAL PROGRESSION AFTER OSIMERTINIB TREATMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, 100021, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH MENINGEAL PROGRESSION AFTER OSIMERTINIB TREATMENT PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WITH MENINGEAL PROGRESSION AFTER OSIMERTINIB TREATMENT